Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03565913 · ClinicalTrials.gov registry record · Phase 2
Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V
A Phase 2 study of CKD Stage 5, sponsored by University of Texas Southwestern Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 269
- Enrollment target
- 1
- Study location
NCT03565913 is a Phase 2 study of CKD Stage 5 that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 269 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03565913, a Phase 2 study of CKD Stage 5, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 269 participants
- Enrollment target
- 1
- Study location
Study Summary
The Investigators plan to conduct a long-term trial to explore therapeutic implications of effervescent calcium magnesium citrate (EffCaMgCit) in CKD Stage V (end stage renal disease on hemodialysis). The Investigators will test the hypothesis that EffCaMgCit would retard the formation of calciprotein particles (CPP) in CKD Stage V, thereby reducing the degree of coronary artery and peripheral artery calcification and cardiac hypertrophy-fibrosis. Aim 1. To compare cardiovascular risk of EffCaMgCit versus CaAcS in CKD Stage V Aim 2. To show that EffCaMgCit reduces putative serum FGF23, and increases beneficial alkali load Aim 3. To compare parameters of bone turnover and bone mineral density (BMD) between EffCaMgCit and CaAcS groups
Conditions Studied
Interventions
- DRUG EffCaMgCit
- OTHER CaAcS
Study Locations (1)
Texas
- DaVita Dialysis Centers - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2017-01-22 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03565913
The ClinicalTrials.gov registry entry for NCT03565913 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 269 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CKD Stage 5 appearing as the primary indexed condition, and to 2 interventions - of which EffCaMgCit is the first listed.
NCT03565913 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03565913 about?
NCT03565913 is a clinical study titled "Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V". The Investigators plan to conduct a long-term trial to explore therapeutic implications of effervescent calcium magnesium citrate (EffCaMgCit) in CKD Stage V (end stage renal disease on hemodialysis). The Investigators will test the hypothesis that EffCaMgCit would retard the formation of calciprote...
What is the current status of trial NCT03565913?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 269 participants. The study started on 2017-01-22. Estimated completion is 2025-12-31.
What conditions does trial NCT03565913 study?
This clinical trial studies the following conditions: CKD Stage 5.
What interventions are being tested in trial NCT03565913?
The interventions under investigation include: EffCaMgCit (DRUG), CaAcS (OTHER).
Who is sponsoring clinical trial NCT03565913?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03565913 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.